Invitation Accepted: Biopharma Leaders Will Testify At Senate Hearing On Pricing
Executive Summary
In addition to fielding tough questions about pricing practices at the session, executives may announce new voluntary efforts to lower drug costs and will offer their own ideas for legislation.
You may also be interested in...
HHS' 2018 Greatest Hits: Azar Touts Record FDA Generic Approvals, Drug Pricing And Opioid Actions
In State of the Department speech and HHS annual report, Secretary Azar trumpets historic number of approvals by FDA, and price cuts, roll backs or freezes by 'more than a dozen drug companies.'
Sanofi Releases Annual Drug Price Report Ahead Of Senate Hearing
Sanofi's annual report on its drug price increases echoed a theme heard during recent 2018 earnings calls, with list price hikes offset by rebates resulting in a net price decline.
Sanofi Releases Annual Drug Price Report Ahead Of Senate Hearing
Sanofi's annual report on its drug price increases echoed a theme heard during recent 2018 earnings calls, with list price hikes offset by rebates resulting in a net price decline.